机译:Axitinib与Toripalimab组合,一种用于转移性粘膜黑素瘤的患者的人源化免疫球蛋白G(4)单克隆抗体,用于转移粘膜黑素瘤的患者:开放标签相IB试验
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
0RigiMed Shanghai Peoples R China;
Shanghai Junshi Biosci Shanghai Peoples R China;
Shanghai Junshi Biosci Shanghai Peoples R China;
Shanghai Junshi Biosci Shanghai Peoples R China;
Shanghai Junshi Biosci Shanghai Peoples R China;
Shanghai Junshi Biosci Shanghai Peoples R China;
Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;
Peking Univ Canc Hosp &
Inst Beijing Peoples R China;
机译:Axitinib与Toripalimab组合,一种用于转移性粘膜黑素瘤的患者的人源化免疫球蛋白G(4)单克隆抗体,用于转移粘膜黑素瘤的患者:开放标签相IB试验
机译:414 POSTER对患有局部晚期或转移性实体瘤的患者进行人源化单克隆抗体(HuMAb)TRC093的I期开放标签剂量递增研究,该抗体是与裂解的胶原蛋白结合的血管生成抑制剂
机译:414 POSTER对患有局部晚期或转移性实体瘤的患者进行人源化单克隆抗体(HuMAb)TRC093的I期开放标签剂量递增研究,该抗体是与裂解的胶原蛋白结合的血管生成抑制剂
机译:使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
机译:靶向抗死亡受体5的人源化单克隆抗体tigatuzumab(CS-1008)与吉西他滨联合用于未经化疗或转移性胰腺癌的初治患者的第2期多中心开放标签研究
机译:抗CD37单克隆抗体,BI 836826的相位IB,开放标签,剂量升级试验,与吉西他滨和Oxaliplatin组合在复发/难治性弥漫性大B细胞淋巴瘤患者中
机译:psma细胞外区特异性人源化单克隆抗体:前列腺癌患者的剂量递增试验